Search results for: 'prenatal and postnatal'
- Did you mean
- prenatal ad postnatal
- Related search terms
- AND (SELECT (CASE WHEN (3989=1399) THEN NULL ELSE CTXSYS.DRITHSX.SN(1,3989) END) FROM DUAL) IS NULL
- AND (SELECT (CASE WHEN (4327=4327) THEN NULL ELSE CTXSYS.DRITHSX.SN(1,4327) END) FROM DUAL) IS NULL
- AND (SELECT (CASE WHEN (1509=3753) THEN NULL ELSE CTXSYS.DRITHSX.SN(1,1509) END) FROM DUAL) IS NULL-- wUvH
- AND (SELECT 1827 FROM (SELECT(SLEEP(20)))zydf)
- android edg pos terminals forecast 2024
-
19 Jan 2024  |  Europe  |  Market Research
European Non-invasive Prenatal Testing Market, Forecast to 2028
Driving Progress in Screening Techniques Amplifies Accessibility and Adoption of NIPT, Cultivating a Broader Patient Engagement in Europe
The European non-invasive prenatal testing (NIPT) market will experience significant growth thanks to technological advancement, increasing awareness among expectant parents, and the rising incidence of chromosomal abnormalities in fetuses. The market has experienced a surge in demand due to its products non-invasive nature compared to traditional...
$4,950.00 -
03 Oct 2022  |  Global  |  Market Research
Global Prenatal Genetic Testing—Forecast to 2026
Innovation Culture in Screening Drives Prenatal Genetic Testing Growth and Makes it Accessible to More Patients
New technological advances in prenatal genetic testing include the enhancement of the next-generation sequencing (NGS) technology, chromosomal microarray analysis (CMA) tool, and PCR TaqMan. These improve precision and specificity in genome profiling, augment the efficiency and reliability of testing, and streamline workflow. The study will help...
$4,950.00 -
30 Nov 2017  |  Europe  |  Market Research
Growth Opportunities in European Prenatal Genetic Testing Market, Forecast to 2021
Non-invasive Prenatal Testing (NIPT) Driven by the Adoption of Next Generation Sequencing (NGS) Techniques for Screening is Driving Market Growth
Prenatal genetic tests are predominantly used to test disorders such as aneuploidies in chromosomes 21, 18, 13 and carrier screens. They are gaining momentum in EU due to enhanced assay outcomes through non-invasive methodologies using next generation sequencing (NGS) techniques, increasing number of women choosing to undergo pregnancy at an advanc...
$3,000.00 -
12 Aug 2021  |  North America  |  Frost Radar
Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021
A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines
Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving ac...
$4,950.00 -
20 Apr 2023  |  Asia Pacific  |  Market Outlook
Asia-Pacific Next-generation Diagnostics Outlook, 2023
The Renewed Focus on Infectious Diseases Outside COVID-9, Oncology, Cardiovascular, Diabetes, and Prenatal Care will Drive Market Growth
The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...
$4,950.00 -
03 Apr 2023  |  Global  |  Market Outlook
Global Next generation Diagnostics, Outlook 2023
Automation and Digitization Drive the Next Growth Phase Post-COVID-19
As COVID-19 transitions to the endemic phase, automation solutions and smart, connected laboratories will catalyze recovery in the next-generation diagnostics industry. The COVID-19 pandemic left a lot of installed capacity in laboratories and healthcare centers. To take advantage of this situation, it is necessary for industry players to focus on ...
$4,950.00 -
12 Sep 2016  |  North America  |  Market Research
Price Point Analysis for Laboratory Developed Tests (LDTs) and FDA Regulated Tests
Discover the Perfect Assay Price Point to Remain Competitive
The main objective of this research is to estimate test volumes and unit prices for a wide variety of LDTs (genetic) and a few high volume FDA tests for selective therapeutic areas. The tests are categorized by their intended uses across the diagnostic spectrum (risk assessment, screening, diagnosis, staging and prognosis, therapy selection, therap...
$1,500.00 -
05 Oct 2018  |  North America  |  Market Research
Growth Opportunities in the Global Liquid Biopsy Market, 2018
Companies are Vying for a Higher Market Position in the Early Cancer Screening Market
Liquid biopsy (CTCs and ctDNAs) is slowly gaining momentum in clinical care given its advantages over the traditional tissue-based gold standard methods. Short-term applications in cancer care range from risk assessment to cancer recurrence monitoring. Despite the proven advantages, there is still a significant number of barriers to adoption such a...
$4,950.00 -
23 Mar 2017  |  Asia Pacific  |  Market Research
APAC Molecular Diagnostics Market, Forecast to 2021
Pharmerging Economies with Rising Healthcare Demands will Accentuate Growth
The molecular diagnostics (MDx) market in APAC is witnessing rapid growth due to two main factors: the high adoption of MDx tests for infectious diseases applications in emerging countries, and the advent of innovative diagnostic solutions in cancer and NGS based solutions that are gaining pace in Asia. Multinational companies have not only identif...
$4,950.00 -
17 Jun 2024  |  Global  |  Market Research
Diagnostics Lab Automation and Monitoring Solutions Growth Opportunities
The Intersection of Automation and Digital Data Exchange Unlocks Value for Diagnostics Labs
The pathology workforce shortage, accuracy concerns, and uneven distribution of prices and resources are persistent challenges for the diagnostics sector. Lab test results are the foundation of future human health, influencing 70% of clinical decisions. A surge in lab tests yearly volume will result from persistent trends, including aging popu...
$4,950.00